International Stem Cell Corp. (ISCO) Stays the Cou
Post# of 124
Posted On: 10/20/2015 5:26:08 PM
International Stem Cell Corp. (ISCO) Stays the Course in BioTech’s Regenerative Medicine Space
International Stem Cell Corp. continues its pursuit of advancing regenerative medicine through its use and research of stem cells in the white hot biotechnology space. ISCO uses parthenogenesis, a stem cell technology that makes use of unfertilized eggs to address immune system rejection. The eggs being used have mirroring sets of human leukocyte antigen genes (HLA) that reduce the chance of immune system rejection. Not to be overlooked, it’s worth noting that one line of these cells can treat multiple millions of people. The company can draw human parthenogenetic neural stem cells (hpNSC) from the unfertilized eggs for self-renewing processes that are integral to the degeneration process.
Following continuous successful testing, International Stem Cell Corp. suggests that their human parthenogenetic neural stem cells can take the place of dead and dying neurons while also protecting existing ones when transplanted into the brain of someone with Parkinson’s disease. Further, company researchers and scientists are progressing toward developing human retinal epithelium (RPE) cells that are used in the treatment of eye diseases like age-related macular degeneration. Along with that research, the company is one of the world’s select few to develop a method for creating corneal tissue and cells to treat blindness.
International Stem Cell has recently announced its development of technology that creates functional cartilage from a person’s skin to treat a joint disease that erodes cartilage infamously known as osteoarthritis. The company is also making strides aside from therapeutic systems that, according to Chief Scientific Officer, Ruslan Semechkin, PhD, “can potentially be treated with the patient’s own cells.”
Running concurrent with its work in the area of regenerative techniques, International Stem Cell Corp. runs a cosmeceutical line called Lifeline Skin Care Inc. This business makes cosmetic skin care products all over the globe. The company’s research and development in this area uses parthenogenetic stem cells, vitamins and minerals to create a rejuvenating serum leading to healthier skin.
International Stem Cell Corp. works on therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. The company’s primary technology of parthenogenesis nets the creation of pluripotent human stem cells from unfertilized oocytes. Company scientists have created the first parthenogenetic, homozygous stem cell line that is considered by many to be a source of therapeutic cells for hundreds of millions of individuals of differing genders, racial background and ages.
For more information about the company, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
International Stem Cell Corp. continues its pursuit of advancing regenerative medicine through its use and research of stem cells in the white hot biotechnology space. ISCO uses parthenogenesis, a stem cell technology that makes use of unfertilized eggs to address immune system rejection. The eggs being used have mirroring sets of human leukocyte antigen genes (HLA) that reduce the chance of immune system rejection. Not to be overlooked, it’s worth noting that one line of these cells can treat multiple millions of people. The company can draw human parthenogenetic neural stem cells (hpNSC) from the unfertilized eggs for self-renewing processes that are integral to the degeneration process.
Following continuous successful testing, International Stem Cell Corp. suggests that their human parthenogenetic neural stem cells can take the place of dead and dying neurons while also protecting existing ones when transplanted into the brain of someone with Parkinson’s disease. Further, company researchers and scientists are progressing toward developing human retinal epithelium (RPE) cells that are used in the treatment of eye diseases like age-related macular degeneration. Along with that research, the company is one of the world’s select few to develop a method for creating corneal tissue and cells to treat blindness.
International Stem Cell has recently announced its development of technology that creates functional cartilage from a person’s skin to treat a joint disease that erodes cartilage infamously known as osteoarthritis. The company is also making strides aside from therapeutic systems that, according to Chief Scientific Officer, Ruslan Semechkin, PhD, “can potentially be treated with the patient’s own cells.”
Running concurrent with its work in the area of regenerative techniques, International Stem Cell Corp. runs a cosmeceutical line called Lifeline Skin Care Inc. This business makes cosmetic skin care products all over the globe. The company’s research and development in this area uses parthenogenetic stem cells, vitamins and minerals to create a rejuvenating serum leading to healthier skin.
International Stem Cell Corp. works on therapeutic applications of human parthenogenetic stem cells and the development and commercialization of cell-based research and cosmetic products. The company’s primary technology of parthenogenesis nets the creation of pluripotent human stem cells from unfertilized oocytes. Company scientists have created the first parthenogenetic, homozygous stem cell line that is considered by many to be a source of therapeutic cells for hundreds of millions of individuals of differing genders, racial background and ages.
For more information about the company, visit www.internationalstemcell.com
Please read full disclaimers at http://disclaimer.missionir.com
(0)
(0)